Canada’s NanoVation Therapeutics, a privately-held platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, has announced a multi-year partnership with Danish drugmaker Novo Nordisk. 18 September 2024
Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. 17 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). 6 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Lexicon Pharmaceuticals yesterday announced that a post-hoc analysis of Phase III data from the SCORED clinical trial demonstrated that Inpefa (sotagliflozin) reduced the risk of major adverse cardiovascular events. 4 September 2024
Anthos Therapeutics has reported a new analysis from the landmark AZALEA-TIMI 71 study, demonstrated that the investigational Factor XI inhibitor abelacimab was associated with remarkably low levels of periprocedural bleeding in patients with atrial fibrillation (AFib). 3 September 2024
Germany’s Bayer (BAYN: DE) has presented detailed results from its Phase III OCEANIC-AF trial for the blood thinner asundexian at the annual meeting of the European Society of Cardiology (ESC). 3 September 2024
Novo Nordisk’s semaglutide—marketed under the names Wegovy and Ozempic—have already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too. 2 September 2024
UK-based George Medicines has announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London. 2 September 2024
Cytokinetics (Nasdaq: CYTK) has presented new data on aficamten, its experimental cardiac myosin inhibitor, at the European Society of Cardiology Congress 2024. 2 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
The European subsidiary of Japanese drugmaker Daiichi Sankyo announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. 2 September 2024
Regulatory news last week included European Commission approval for Swiss drugmaker Basilea’s antibacterial Cresemba, triggering a milestone payment from partner Pfizer. On the research front, Neurocrine Biosciences released mixed results from a Phase II study of its NBI-1117568 as a treatment for schizophrenia. Also, Alnylam Pharmaceuticals reported new Phase III data on its vutrisiran in cardiomyopathy. Swiss pharma giant Novartis inked collaboration with Lindy Bioscience aiming to turn biologic drugs into at home injectables, US major Eli Lilly launched a single vial formulation of its fast selling obesity drug Zepbound at a price discount of around 50% compared with other GLP-1 medicines. 1 September 2024
US RNAi therapeutics company Alnylam Pharmaceuticals today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 August 2024
Flagship Pioneering yesterday demonstrated further acceleration in its strategic partnership with Pfizer, announcing two research programs with Flagship-founded Quotient Therapeutics. 29 August 2024
Novartis today announced positive top-line results from twice-yearly Leqvio (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. 28 August 2024
US pharma giant Merck & Co has announced that the European Commission (EC) has approved Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) functional class (FC) II to III, to improve exercise capacity. 27 August 2024
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
French privately-held pharma company Servier has announced its financial results for the 2021/22 financial year, highlighting the major steps of its ongoing transformation. 3 February 2023
US drugmaker Bristol Myers Squibb was trading 2% higher at lunchtime Thursday after presenting its fourth quarter and full year 2022 financial results. 2 February 2023
US biotech giant Amgen released mixed financial results for the fourth quarter and full year 2022 versus comparable periods in 2021, after markets closed on Monday. 1 February 2023
In a sudden turn of events, Novartis' Entresto (sacubitril/valsartan) patent has been reinstated in India, after a two-judge bench stayed a previous order that invalidated it. 24 January 2023
As a blockbuster heart failure drug by Swiss pharma giant Novartis goes off-patent, several Indian drug majors are rushing to market with their generic applications. The patent loss of Entresto (sacubitril/valsartan) has brought on significant disruptions in India’s cardiology sector. High courtroom drama ensued a few days before the patent loss and had everyone on tenterhooks, reports The Pharma Letter’s India correspondent. 20 January 2023
California, USA-based clinical-stage biopharmaceutical company 89bio’s pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says analyst. 17 January 2023
The cardiomyopathies market in the 68 major world markets (68M) is set to grow from $3.07 billion in 2021 to $9.63 billion in 2031 at a compound annual growth rate (CAGR) of 12.1%. 16 January 2023
The past week kicked off with several M&A deals being announced. The largest of these was by UK pharma major AstraZeneca revealing that is acquiring CinCor Pharma for up to $1.8 billion, with the aim of expanding it cardiorenal portfolio and pipeline as well as blood pressure drug baxdrostat. Also, French drugmaker Ipsen announced a takeover bid for USA-based Albireo in a deal worth almost $1 billion, bringing with it rights to liver disease drug Bylvay. Arecor Therapeutics reached a key milestone in the development of the ready-to-use injectable AT307 in its partnership with Hikma Pharmaceuticals but the latter also returned rights to another candidate, AT282. Privately-held US mRNA specialist Anima Biotech entered into a collaboration with US pharma major AbbVie to develop cancer and immune disorder therapies. 15 January 2023
US neuromuscular and cardiac diseases specialist Solid Biosciences and privately-held Dutch biotech Phlox Therapeutics have announced a strategic collaboration focused on genetic cardiac diseases. 12 January 2023
Research from industry analyst GlobalData finds that western companies are likely to play an important role in providing new cardiovascular disease (CVD) management options in China. 12 January 2023
Presentations from German group Bayer at the JP Morgan Healthcare Conference have rallied investors’ confidence in the company’s mid-term prospects. 11 January 2023
After an active M&A year in 2022, UK pharma major AstraZeneca kicked off 2023 with an agreement to acquire USA-based clinical stage biotech CinCor Pharma. 9 January 2023
A growing number of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) coming into India have become 25% to 35% more expensive as reports of Covid infections spiral out of control in China, squeezing margins and increasing drug prices. The Indian government's production linked incentive (PLI) scheme for the promotion of domestic manufacturing of critical KSMs, drug intermediates (DIs) and APIs is soon set to come to the aid of many domestic players, reports The Pharma Letter’s India correspondent. 29 December 2022
Indian generics major Zydus Lifesciences, formerly known as Cadila Healthcare, subsidiary Zydus Worldwide has received final approval from the US Food and Drug Administration (FDA) to market Selexipag Tablets, 200mcg, 400mcg, 600mcg, 800mcg, 1,000mcg, 1,200mcg, 1,400mcg, and 1,600mcg. 22 December 2022
Switzerland-based Idorsia today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, the firm’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension. 20 December 2022
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022